Sudeep Pharma Limited IPO

₹14,825 Min Investment

Issue Opening Date
November 21, 2025
Issue Closing Date
November 25, 2025
Price Band
Rs 563 to Rs 593 per share
Lot Size
25 Shares
IPO Fact Sheet
Download Now
Sudeep Pharma Limited IPO ClosedOpen

₹14,825

Min. investment

Snapshot

Sudeep Pharma Limited, based in Vadodara, is a leading Indian manufacturer specializing in specialty mineral phosphates and pharmaceutical excipients for the pharmaceutical, nutraceutical, food, and battery industries. The company is recognized as a pioneering battery-grade iron phosphate supplier outside China and is establishing Asia’s largest mineral phosphate facility, positioning India as a key regional player in EV battery supply chains. Sudeep Pharma addresses growing global demand for safer, sustainable materials critical for electric vehicles and energy storage.

Company Vision

The vision of Sudeep Pharma Limited is to emerge as a global leader in specialty mineral phosphates and pharmaceutical excipients by leveraging innovation, quality, and sustainable practices. The company aims to expand its footprint in critical industries like pharmaceuticals, nutraceuticals, food, and battery materials while fostering technological advancement and environmental stewardship. Sudeep Pharma aspires to power the future of healthcare and clean energy through trusted, safe, and high-performance products, driving value for stakeholders and contributing to a healthier planet.

Growth Prospects

Sudeep Pharma Limited's growth prospects are anchored in expanding its leadership in specialty mineral phosphates and pharmaceutical excipients amid growing global demand. The company is strategically positioned to capitalize on rising needs in pharmaceuticals, nutraceuticals, food, and electric vehicle battery materials, especially with Asia’s largest mineral phosphate facility underway. Strong export presence in key markets, ongoing product innovation, acquisition of Nutrition Supplies and Services Ireland Limited, and favorable government incentives contribute to robust expansion potential. Challenges include regulatory compliance, geopolitical risks, and tariff impacts, but long-term outlook remains strong with market growth in related sectors.

Risk

Sudeep Pharma Limited faces several risks including customer concentration, regulatory compliance, and operational disruptions. Dependence on a limited number of customers and significant revenue from pharmaceuticals and nutrition segments expose the company to demand fluctuations. Manufacturing facility audits, quality control issues, and regulatory inspections can impact operations and reputation. Export sales are vulnerable to geopolitical risks, tariffs, and trade restrictions. Supply chain interruptions and raw material price volatility may affect production. Integration challenges from acquisitions and ventures into new sectors add further uncertainties, potentially impacting financial performance and growth.

Sudeep Pharma Limited Details

Issue Opening Date Friday, November 21,2025
Issue Closing Date Tuesday, November 25, 2025
Price Band Rs. 563/- to Rs. 593/- per equity share.
Bid Lot 25 Shares
Face value Rs. 1 per share
No. of Share 1,50,92,750 shares
Issue Size (aggregating up to Rs. 895.00 Cr)
Fresh Issue (aggregating up to Rs. 95.00 Cr)
Offer for Sale 1,34,90,726 shares of Rs 1 (aggregating up to Rs 800.00 Cr)

Sudeep Pharma Limited Timeline (Tentative Schedule)

IPO Open Date Fri, Nov 21, 2025
IPO Close Date Tue, Nov 25, 2025
Tentative Allotment Wed, Nov 26, 2025
Initiation of Refunds Thu, Nov 27, 2025
Credit of Shares to Demat Thu, Nov 27, 2025
Tentative Listing Date Fri, Nov 28, 2025
Cut- off time for UPI mantate Confirmation 5 PM on Tue, Nov 25, 2025

Sudeep Pharma Limited Financial Information (Restated)

Amount in Cr. Q1 FY2026 FY2025 FY2024 FY2023
Total Assets 922.26 717.17 513.87 420.11
Total Revenue 130.08 511.33 465.38 438.26
Profit After Tax 31.27 138.69 133.15 62.32
EBITDA 48.57 199.28 187.76 98.64
Net Worth 688.32 497.53 359.07 226.29
Reserves and Surplus 668.52 481.11 354.59 221.88
Total Borrowing 135.97 135.25 75.03 82.26
Sudeep Pharma Limited IPO  Registrar

MUFG Intime India Pvt.Ltd.

+91-22-4918 6270
sudeeppharma.ipo@in.mpms.mufg.com
https://linkintime.co.in/Initial_Offer/public-issues.html

Prospectus Document

Official Red Herring Prospectus (RHP)

For detailed company and issue information

SEBI Registration No: NSE Cash: INB231219636 | SEBI Registration No: NSE Derivative: INF231219636 | SEBI Registration No: BSE Cash: INB011219632 | SEBI Registration No: MCX-SX: INE261219636 | SEBI Registration No: NSE Currency: INE231219636 | SEBI Registration No: USE: INE271219631 | SEBI Registration No: CDSL: IN-DP-CDSL-3242005 | NCDEX Membership No: 00635 | MCX Membership No: 28850 | NSEL Membership No: 10650 | RBI Registration No: NBFC: N-14.03215 | IRDA Registration Number : CB-066/03 | AMFI Registration No : ARN -0032| SEBI Registration No: Merchant Banker: INM000007508

* Mutual fund investments are subject to market risks. Please read the scheme information and other related documents carefully before investing.